Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Department of Andrology, Peking University Third Hospital, Beijing, China.
Andrology. 2023 Sep;11(6):1175-1187. doi: 10.1111/andr.13390. Epub 2023 Feb 17.
Recently, dapoxetine has been widely accepted to treat premature ejaculation by fast-inhibiting 5-hydroxytryptamine reuptake. However, dapoxetine is not suitable for all premature ejaculation patients in clinical treatment. We need to investigate and reveal the mechanism deeply to solve this problem.
To investigate and reveal the function of dopamine D4 receptor in dapoxetine medicated premature ejaculation treatment.
A rat model was used to screen rapid ejaculators. The molecular mechanisms of histone serotonylation-mediated regulation of dopamine D4 receptor were demonstrated by chromatin immunoprecipitation, DNA pull-down, mass spectrometry analysis, and coimmunoprecipitation experiments. The biological function of dopamine D4 receptor was investigated through in vivo experiments by intrathecal injection of shDRD4 to knockdown dopamine D4 receptor.
In this study, we found that dapoxetine increased expression of 5-hydroxytryptamine and dopamine D4 receptor. We demonstrated that dapoxetine increased levels of 5-hydroxytryptamine, which promoted histone serotonylation (H3K4me3Q5ser) and transcription factor myeloid zinc-finger 1 complex binding on the dopamine D4 receptor promoter, upregulated the expression of dopamine D4 receptor and thus delayed ejaculation.
In this study, we demonstrated that dapoxetine increased the levels of 5-hydroxytryptamine, which promoted histone serotonylation and myeloid zinc-finger 1 complex binding to the dopamine D4 receptor promoter and upregulated the expression of dopamine D4 receptor, thus delaying ejaculation.
It is a novel mechanism that dapoxetine take effect of premature ejaculation treatment through upregulating the dopamine D4 receptor, which indicated that upregulated dopamine D4 receptor would enhance the dapoxetine effect in premature ejaculation treatment. This may lead to the development of novel therapeutic interventions for premature ejaculation.
最近,达泊西汀通过快速抑制 5-羟色胺再摄取而被广泛接受用于治疗早泄。然而,在临床治疗中,达泊西汀并不适合所有早泄患者。我们需要深入研究和揭示机制,以解决这个问题。
探讨和揭示多巴胺 D4 受体在达泊西汀治疗早泄中的作用。
使用大鼠模型筛选快速射精者。通过染色质免疫沉淀、DNA 下拉、质谱分析和共免疫沉淀实验,证实了组蛋白 5-羟色胺化介导的调节多巴胺 D4 受体的分子机制。通过鞘内注射 shDRD4 以敲低多巴胺 D4 受体,在体内实验中研究了多巴胺 D4 受体的生物学功能。
在这项研究中,我们发现达泊西汀增加了 5-羟色胺和多巴胺 D4 受体的表达。我们证明,达泊西汀增加了 5-羟色胺的水平,促进了组蛋白 5-羟色胺化(H3K4me3Q5ser)和髓样锌指 1 复合物在多巴胺 D4 受体启动子上的结合,上调了多巴胺 D4 受体的表达,从而延迟射精。
在这项研究中,我们证明了达泊西汀增加了 5-羟色胺的水平,促进了组蛋白 5-羟色胺化和髓样锌指 1 复合物与多巴胺 D4 受体启动子的结合,上调了多巴胺 D4 受体的表达,从而延迟射精。
达泊西汀通过上调多巴胺 D4 受体发挥治疗早泄的作用是一种新的机制,这表明上调多巴胺 D4 受体将增强达泊西汀治疗早泄的效果。这可能导致开发治疗早泄的新治疗干预措施。